SARS-CoV-2 induces inflammasome-dependent pyroptosis and

downmodulation of HLA-DR in human monocytes, which can be

prevented by atazanavir

André C. Ferreira[1,2,10#*,] Vinicius Cardoso Soares[1,9#], Isaclaudia G. de Azevedo-

Quintanilha[1], Suelen da Silva Gomes Dias[1], Natalia Fintelman-Rodrigues[1,10], Carolina Q.

Sacramento[1,10], Mayara Mattos[1,10], Caroline S. de Freitas[1,10], Jairo R. Temerozo[3,4], Lívia

Teixeira[1], Eugenio Damaceno Hottz[1,5], Ester A Barreto[1], Camila R. R. Pão[1], Lohanna

Palhinha[1], Milene Miranda[6], Dumith Chequer Bou-Habib[3,4], Fernando A. Bozza[7,8],

Patrícia T. Bozza[1] , Thiago Moreno L. Souza[1,10*]

1 – Laboratório de Imunofarmacologia, Instituto Oswaldo Cruz (IOC), Fundação

Oswaldo Cruz (Fiocruz), Rio de Janeiro, RJ, Brazil.

2 – Universidade Iguaçu, Nova Iguaçu, RJ, Brazil.

3 – Laboratório de Pesquisas sobre o Timo, IOC, Fiocruz, Rio de Janeiro, RJ, Brazil.

4 – National Institute for Science and Technology on Neuroimmunomodulation, Oswaldo

Cruz Institute, Fiocruz, Rio de Janeiro, RJ, Brazil.

5 – Laboratório de Imunotrombose, Departamento de Bioquímica, Universidade Federal

de Juiz de Fora, Juiz de Fora, MG, Brazil.

6 – Laboratório de Vírus Respiratório e do Sarampo, IOC, Fiocruz, Rio de Janeiro, RJ,

Brazil.

7 – Instituto Nacional de Infectologia Evandro Chagas, Fiocruz, Rio de Janeiro, RJ,

Brazil.

8 – Instituto D'or de Pesquisa e Ensino, Rio de Janeiro, RJ, Brazil.

9 - Program of Immunology and Inflammation, Federal University of Rio de Janeiro,

UFRJ, Rio de Janeiro, RJ, Brazil.

10 - Centro De Desenvolvimento Tecnológico Em Saúde (CDTS), Fiocruz, Rio de

Janeiro, Brasil.

# These authors contributed equally to this work

* corresponding author

Abstract

Infection by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been associated with leukopenia and uncontrolled inflammatory response in critically ill patients. A better comprehension of SARS-CoV-2-induced monocytes death is essential for the identification of therapies capable to control the hyper-inflammation and reduce viral replication in patients with COVID-19. Here, we show that SARS-CoV-2 induces inflammasome activation and cell death by pyroptosis in human monocytes, experimentally infected and in patients under intensive care. Pyroptosis was dependent on caspase-1 engagement, prior to IL-1ß production and inflammatory cell death. Monocytes exposed to SARS-CoV-2 downregulate HLA-DR, suggesting a potential limitation to orchestrate the immune response. Our results originally describe the mechanism by which monocytes, a central cellular component recruited from peripheral blood to respiratory tract, succumb in patients with severe 2019 coronavirus disease (COVID-19), and emphasize the need for identifying anti-inflammatory and antiviral strategies to prevent SARS-CoV-2-induced pyroptosis.

Introduction

Severe acute respiratory coronavirus 2 (SARS-CoV-2), the etiological agent of the 2019 coronavirus disease (COVID-19), emerged in China, causing a major public health burden in decades. Patients with COVID-19 may develop an asymptomatic or mild disease or be affected by the life threatening acute respiratory distress syndrome (ARDS), which is characterized by elevated serum levels of proinflammatory mediators, the cytokine storm (1-3). In the respiratory tract of patients with severe COVID-19, monocytes/macrophages may be the main source of uncontrolled levels of the pro-inflammatory mediators TNF-α and IL-6 (4). Plasmatic levels of IL-6 have been associated with mortality, intensive care admission and hospitalization, representing a poor prognostic factor for COVID-19 (5). The uncontrolled inflammation promoted by SARS-CoV-2 in severe COVID-19 is not acute, it negatively associates with viral loads in nasopharyngeal swabs and represents an important event from 7 to 10 days after onset of illness (6-7). Along with uncontrolled pro-inflammatory response, severe COVID-19 associates with high levels of tissue insult, judged by increased levels of lactate dehydrogenase (LDH) and D-dimer in the plasma and leukopenia (6-8). In addition, a

severe immune dysregulation with low antigen presenting capacity is evidenced by
reduced expression of HLA-DR in monocytes during COVID-19, which is strongly
associated with severe respiratory failure (4).

The leucopenia and increased LDH levels in the plasma of patients with severe
COVID-19 seem to precede the cytokine storm (9-14). Moreover, in other virus-induced
cytokine storm episodes in the respiratory tract, such as induced by influenza A virus,
monocytes and macrophages are severely affected (9). We thus hypothesized that SARS-
COV-2-induced cell death of monocytes could impair a resolutive cytokine release.
Indeed, we found that SARS-CoV-2 triggers inflammasome activation, leading to
pyroptosis in human monocytes, either by experimental or natural infection. Pyroptosis
was dependent on caspase-1 engagement, prior to IL-1ß production and dysregulation of
cytokine release. Monocytes that survive after SARS-CoV-2 challenge downregulate
HLA-DR, being less likely to properly orchestrate the immune response. Finally, we
show that the reproposed antiviral drugs atazanavir could block this deleterious loop in
favor of the host.

Material and Methods

Reagents

Atazanavir (ATV) and Ribavirin were received as donations from Instituto de
Tecnologia de Fármacos (Farmanguinhos, Fiocruz). The antiviral Lopinavir/ritonavir
(4:1 proportion) was pruchased from AbbVie (Ludwingshafen, Germany). ELISA assays
were purchased from R&D Bioscience. Lipopolysacchadides - LPS, adenosine
triphosphate (ATP), the specific inhibitor of caspase-1 (AC-YVAD-CMK), pan-caspase
inhibitor (ZVAD-FMK), RIPK1 (Necrostatin-1 – Nec-1) and IL-1 receptor (IL-1RA)
were all purchased from Sigma-Aldrich (St. Louis, MO, USA). All small molecule
inhibitors were dissolved in 100 % dimethylsulfoxide (DMSO) and subsequently diluted
at least 10^4-fold in culture or reaction medium before each assay. The final DMSO
concentrations showed no cytotoxicity. The materials for cell culture were purchased
from Thermo Scientific Life Sciences (Grand Island, NY), unless otherwise mentioned.

Cells and Virus

African green monkey kidney (Vero, subtype E6) cells were cultured in DMEM high glucose supplemented with 10 % fetal bovine serum (FBS; HyClone, Logan, Utah) and 100 U/mL penicillin, and 100 μg/mL streptomycin (P/S). Vero cells were incubated at 37°C in 5 % CO_2 atmosphere.

Human primary monocytes were obtained through plastic adherence of peripheral blood mononuclear cells (PBMCs), which were obtained from buffy coat preparations of healthy donors by density gradient centrifugation (Ficoll-Paque, GE Healthcare). In brief, PBMCs (2.0×10^6 cells) were plated onto 48-well plates (NalgeNunc) in RPMI-1640 without serum for 2 to 4 h; then, non-adherent cells were removed by washing and the remaining monocytes were maintained in DMEM with 5% human serum (HS; Millipore) and penicillin/streptomycin.

SARS-CoV-2 was isolated and expanded on Vero E6 cells from a nasopharyngeal swab of a confirmed case from Rio de Janeiro, Brazil. Experiments were performed after one passage in cell culture, when Vero E6 cells with DMEM plus 2% FBS in 150 cm^2 flasks were incubated at 37 °C in 5 % CO_2 atmosphere. Cytopathic effect was observed daily and peaked 4 to 5 days after infection. All procedures related to virus culture were handled at biosafety level 3 (BSL3) multiuser facility, according to WHO guidelines. Virus titers were determined as the tissue culture infectious dose at 50% (TCID50/mL). Virus stocks were kept in -80 °C ultralow freezers. The virus strain was sequenced to confirm the virus identity and its complete genome is publicly deposited (GenBank accession no. MT710714).

Yield-reduction assay

Human primary monocytes were infected with multiplicity of infection (MOI) of 0.01 at density of $2-8 \times 10^5$ cells/well in 48-well culture plates, depending on the total cell number from each donor. After 1 h at 37 °C, cells were washed, and various concentrations of compounds were added in DMEM with 2% FBS. After 48 h, the supernatants were harvested and virus replication was quantified by real time RT- PCR and infectious titers by TCID50/mL.

Virus titration

Monolayers of Vero cells (2×10^4 cell/well) in 96-well culture plates were infected
with log- based dilutions of the supernatants containing SARS-CoV-2 for 1 h at 37°C.
The cells were washed and fresh medium with 2% FBS was added. After 3 to 5 days, the
cytopathic effects were scored in at least 10 replicates per dilution by independent readers,
who were blind with respect to source of the supernatant. Reed and Muench scoring
method was employed to determine TCID50/mL.

Flow cytometer analysis

For flow cytometry analysis, monocytes were diluted in labelling buffer (10^6
cells/mL). Then, 100 µL of cell samples were marked with 5 µL of AnnexinV and PI for
15 minutes for cell death evaluation. Around 10,000 gated events were acquired using
FACSCalibur and the analysis was performed using the CellQuest software. Monocytes
were gated through cell size (foward light scatter, FSC) and granularity (side light scatter,
SSC) analysis.

Human monocytes were stained for caspase-1 activity with FAM-YVAD-FMK
(fluorescent-labeled inhibitor of caspase-1 [FLICA] and FAM-FLICA Caspase-3/7
activity or HLA-DR APC.H7 or IgG APC.H7. Caspase-1 and caspase-3/7 activity was
determined via flow cytometry (FACSCalibur) by detecting FLICA fluorescence and
expression of HLA-DR as mean fluorescence intensity (MFI) value for each sample.
Acquisition of data was set to count a total of 10,000 events, and the FLOWJO software
package was used to analyze the data.

Microscopic analysis

Human primary monocytes were plated on glass coverslips at density of $2\text{-}8 \times 10^5$
cells/well in 48-well plates. Infection was performed for 2 h at 37 °C and then fresh
medium with 2% FBS was added. After 24 h, the cells were washed with Binding buffer
and stained with PI (0.5 µg/mL) for 5 minutes. Next, the cells were fixed with 3.7%
formaldehyde for 30 minutes at room temperature. The nuclei were stained with DAPI
(1µg/mL) for 5 min and the coverslips were mounted using an antifade mounting medium

(VECTASHIELD). Fluorescence was analyzed by fluorescence microscopy with an x100

objective lens (Olympus, Tokyo, Japan).

Measurements Inflammatory Mediators and cell death marker

The levels of IL-1ß, TNF-α, IL-6, IL-8 and LDH were quantified in the culture

supernatants from infected and uninfected monocytes using ELISA kits, according to the

manufacturer's intructions (R&D System).

Extracellular lactate dehydrogenase (LDH) was quantified using Doles® kit

according to manufacturer's instructions. In brief, cell culture supernatants were

centrifuged at 5,000 rpm for 1 minute, to remove cellular debris, and then 25 μL were

placed into 96-well plates and incubated with 5 μL of ferric alum and 100 μL of LDH

substrate for 3 minutes at 37 °C. Nicotinamide adenine dinucleotide (NAD, oxidized

form) was added followed by the addition of a stabilizing solution. After 10 minutes, the

reaction was read in a spectrophotometer at 492 nm.

Western blot assay

Cellular extracts of $1x10^6$ cells were homogenized in the RIPA lysis buffer in the

presence of proteinase inhibitor cocktail (Roche), and the protein levels were measured

by BCA protein assay kit. A total of 20 μg of protein was loaded onto a 10% sodium

dodecyl sulfate polyacrylamide gel (SDS-PAGE) for separation by electrophoresis and

the protein bands were then transferred to a polyvinylidene difluoride membranes

(ImmobilonP-SQ, Millipore). The membranes were blocked with 5 % albumin diluted in

Tris-buffered saline containing 0.05 % of Tween 20 for 2 hours at room temperature and

incubated with the specific primary antibodies (Cell Signaling Technology), to detect pro-

caspase-1 and cleaved-caspase-1, after overnight incubation at 4 °C. After washing,

membranes were incubated with secondary antibodies (IRDye® 800CW Goat-anti-

Mouse and IRDye® 680LT Goat anti-Rabbit IgG Antibody, LI-COR, Lincoln) for 30

minutes at RT. The protein bands were visualized by digital fluorescence

(Odyssey® CLx Imaging System), and protein density was analyzed by the ImageJ

software. All the data were normalized by β-actin expression quantification.

Human subjects.

We prospectively enrolled severe COVID19 RT-PCR-confirmed cases, as well as

SARS-CoV-2-negative healthy controls. Blood samples were obtained from 12 patients

with severe COVID-19 within 72 hours from intensive care unit (ICU) admission in two

reference centers (Instituto Estadual do Cérebro Paulo Niemeyer and Hospital Copa Star,

Rio de Janeiro, Brazil). Severe COVID-19 was defined as critically ill patients presenting

viral pneumonia on computed tomography scan and in mechanical ventilation. All

patients had SARSCoV-2 confirmed diagnostic through RT-PCR of nasal swab or

tracheal aspirates. Peripheral vein blood was also collected from 8 SARS-CoV-2-negative

healthy control participants as tested by RT-PCR on the day of blood sampling. The

characteristics of severe (n = 12), and control (n = 8) participants are presented in Table

1. Severe COVID-19 patients usually present older age and higher prevalence of

comorbidities as obesity, cardiovascular diseases and diabetes as in previously reported

patient cohorts. In the present study, the SARS-CoV-2-negative control group was

designed to include subjects of older age and chronic non-communicable diseases, so it

is matched with critically ill COVID-19 patients (Table 1). Patients with acute respiratory

distress syndrome (ARDS) were managed with neuromuscular blockade and a protective

ventilation strategy that included low tidal volume (6 mL/kg of predicted body weight)

and limited driving pressure (less than 16 cmH2O) as well as optimal PEEP calculated

based on the best lung compliance and PaO_2/FiO_2 ratio. In those with severe ARDS and

PaO_2/FiO_2 ratio below 150 despite optimal ventilatory settings, prone position was

initiated. Our management protocol included antithrombotic prophylaxis with enoxaparin

40 to 60 mg per day. Patients did not receive routine steroids, antivirals or other anti-

inflammatory or anti-platelet drugs. The SARS-CoV-2- negative control participants

were not under anti-inflammatory or anti-platelet drugs for at least two weeks. All clinical

information were prospectively collected using a standardized form - ISARIC/WHO

Clinical Characterization Protocol for Severe Emerging Infections (CCPBR).

Ethics statement.

Experimental procedures involving human cells from healthy donors were

performed with samples obtained after written informed consent and were approved by

the Institutional Review Board (IRB) of the Oswaldo Cruz Foundation/Fiocruz (Rio de

Janeiro, RJ, Brazil) under the number 397-07. The National Review Board approved the

study protocol (CONEP 30650420.4.1001.0008), and informed consent was obtained

from all participants or patients' representatives.

Statistical analysis

The assays were performed in blinded way. They were performed by one

professional, codified and read by another fellow. All experiments were carried out at

least three independent times, including a minimum of two technical replicates in each

assay. The dose-response curves used to calculate EC50 and CC50 values were generated

by variable slope plot from Prism GraphPad software 8.0. The equations to fit the best

curve were generated based on R^2 values $\geq$ 0.9. Student's T-test was used to access

statistically significant P values <0.05. The statistical analyses specific to each software

program used in the bioinformatics analysis are described above.

Results

SARS-CoV-2 promotes pyroptosis in human monocytes

To explore the mechanism by which SARS-CoV-2 triggers monocyte death,

human primary monocytes were infected and treated with pharmacological inhibitors of

pyroptosis (AC-YVAD-CMK, an inhibitor of Caspase-1 activity), apoptosis (ZVAD-

FMK, a pan-caspase inhibitor), and necroptosis (Nec-1, an inhibitor of Receptor-

interacting serine/threonine-protein kinase 1; RIPK1). Next, cell death was analyzed by

quantifying the LDH activity in the culture supernatant, and by AnnexinV/propidium

iodide (PI) cell labeling through for flow cytometry and fluorescence microscopy. As

shown in Figure 1A, SARS-CoV-2 increased LDH levels similarly to the positive control,

LPS+ATP (Figure 1A). Whereas AC-YVAD-CMK prevented SARS-COV-2-induced

cell death, ZVAD-FMK and Nec-1 did not affect SARS-CoV-2-induced LDH release

(Figure 1A). Flow cytometry and fluorescence microscopy images demonstrated higher

percentages of PI$^+$ cells in the infected cultures, as well as a significant increase in mean

fluorescence intensity (MFI). Both, LDH leak and PI labeling characterize cell membrane

disruption in human monocytes after SARS-CoV-2 infection (Figure 1B-D). SARS-CoV-

2-induced PI positivity was also prevented by AC-YVAD-CMK treatment (Figure 1B -

D). These data suggest that SARS-CoV-2 infection can induce pyroptosis.

SARS-CoV-2 induces pyroptosis in monocytes through inflammasome activation

To gain insights on the mechanisms of monocyte pyroptosis in SARS-CoV-2 infection, we accessed caspase-1 and IL-1 activation - two key events that require inflammasome's proteolytic activity. To do so, human monocytes were pretreated with AC-YVAD-CMK or the IL-1 receptor antagonist (IL-1RA), and infected with SARS-CoV-2. Cells stimulated with LPS+ATP were used as a positive control of inflammasome activation. We observed that SARS-CoV-2 induced pro-caspase-1 cleavage, similarly to positive control (Figure 2A). Caspase-1 activation was not observed in infected cells pretreated with AC-YVAD-CMK (Figure 2A). To confirm these results, cells were labeled with FAM-YVAD-FLICA (as an indicative of caspase-1 activation) and analyzed by flow cytometry. We found that SARS-CoV-2 infection induced the activation of caspase-1 in monocytes in the same magnitude to the positive control group (Figure 2B). Moreover, SARS-CoV-2-induced caspase-1 activation was a specific event, since we did not observe activation of the apoptotic caspases-3 and -7 in infected monocytes (Figure 2C). Importantly, inhibition of IL-1R engagement reduced SARS-CoV-2-mediated caspase-1 activation and LDH release, suggesting that inflammasome-dependent IL-1β secretion amplify caspase-1 activation and pyroptosis in SARS-CoV-2 infection (Figure 2B and 2D).

Inflammasome activation amplify pro-inflammatory cytokines secretion in infected monocytes

As caspase-1 activity is critical for the production of IL-1β (15,16), we measured the levels of this cytokine in our experiments. Our data show that SARS-CoV-2 infection was able to increase IL-1β production (Figure 2A). This increment was prevented by the treatment with caspase-1 pharmacological inhibitor AC-YVAD-CMK and the pan-caspase inhibitor ZVAD (Figure 2A). To confirm whether the observed effect is specifically related to inflammasome activation, we evaluated the production of IL-8, in which induction is independent of the inflammasomes pathway. SARS-CoV-2 infection induced a higher IL-8 production, which was not prevented by caspase-1 inhibition (Figure 2B). Importantly, caspase-1 specific inhibition, but not pan-caspase or RIPK1 inhibitor, also led to lower levels of the pro-inflammatory cytokines IL-6 and TNF-α, highlighting the participation of the caspase-1-IL-1β axis in inflammatory amplification during SARS-CoV-2 infection. (Figure 3C and 3D).

Infection with SARS-CoV-2 decreases the expression of HLA class II in human monocytes independently of the activation of inflammasomes

To investigate the impact of inflammasome activation and cell death through pyroptosis on the orchestration of anti-SARS-CoV-2 immune response, human monocytes were pretreated with AC-YVAD-CMK or with IL-1RA, and then infected with SARS-CoV-2. Cells were then marked with HLA-DR and analyzed by flow cytometry. We found that SARS-CoV-2 infection induced a decrease in HLA-DR expression in monocytes (Figure 3A and B). However, the inhibition of caspase-1 and IL-1R engagement did not prevent the SARS-CoV-2-mediated decreasing of HLA expression (Figure 3C and D).

Atazanavir prevented inflammasome-dependent pyroptosis

Given our findings that pyroptosis and decreased HLA-DR expression are triggered during SARS-CoV-2 replication, we tested whether atazanavir (ATV), an HIV protease inhibitor recently shown to possess antiviral activity against the new CoV in monocytes (17), could prevent these events. Flow cytometry analysis of SARS-CoV-2-infected monocytes treated with ATV demonstrated a significant reduction in caspase-1 activity, observed by the decreased FAM-YVAD-FLICA labeling (Figure 4A). Other orally available repurposed anti-SARS-CoV-2 drugs, such as lopinavir (LPV) and ribavirin (RBV), did not affect SARS-CoV-2-induced pyroptosis (Figure 4B). Moreover, treatments with ATV did not alter the activity of caspase-1, -3 and -7 in monocytes exposed to LPS and ATP, used as a positive control of pyroptosis (Figure S2), indicating a specific antiviral activity of this drug. Consistently, treatment with ATV also reduced the levels of IL-1β, IL-6 and TNF-α in SARS-CoV-2-infected monocytes, when compared to the untreated cells (Figure 4C-F). ATV did not interfere with the production of IL-8, which is independent of inflammasome engagement (Figure 4D).

We then confirmed whether ATV can prevent SARS-CoV-2-induced pyroptosis. Lower levels of LDH were detected in the supernatants of SARS-CoV-2-infected monocytes treated with ATV when compared to infected and untreated cells (Figure 4G). The treatment with ATV was also able to prevent the decrease of HLA-DR expression in infected monocytes (Figure 4H and I). LPV and RBV did not alter the HLA expression in monocytes infected with SARS-Cov-2 (Figure S3).

Inflammasome activation and pyroptosis are risk factors in critically ill COVID-19 patients

305
306

To clinically validate our findings, we evaluated if monocytes obtained from
critically ill patients with COVID-19 would also display signals of inflammasome
engagement and pyroptosis. Western blot analyzes showed that monocytes from
COVID-19 patients had increased levels of cleaved caspase-1 compared to monocytes
from healthy donors (HD) (Figure 5A). To confirm this result, cells were marked with
FAM-YVAD-FLICA and analyzed by flow cytometry. We observed that monocytes from
COVID-19 patients had increased caspase-1 activation (Figure 5B) and significantly
higher PI+ staining, when compared to monocytes from HD (Figure 5C). Corroborating
with our *in vitro* data, we also detected higher levels of IL-1β in the plasma of critically
ill patients (Figure 5D).

SARS-CoV-2 infection induces inflammasome-dependent pyroptosis and
downmodulation of HLA-DR monocytes, which can be prevented by atazanavir

Representative scheme demonstrating the effect of SARS-CoV-2 infection by
stimulating the production of TNF-alpha and IL-6 and by another way promoting the
assembly of inflammasomes leading to activation of caspase-1 and release of cleaved IL-
1ß and pyroptosis cell death. Release of IL-1ß amplify the activation of inflammasomes
during the SARS-CoV-2 infection. SARS-CoV-2 also induces the HLA-DR
downregulation independently of the activation of inflammasomes and ATV treatment
prevents the formation of inflammasomes with the consequent release of IL-1ß, and also
preserves the expression of HLA-DR in the treated human monocytes.

Discussion

COVID-19 has caused in less than 8 months over 800,000 deaths worldwide (18)
and represent the major public health crisis of the beginning of 21st century, leading to an
unimaginable impact in global economics (19,20). SARS-CoV-2 infection triggers an
uncontrolled inflammatory response and marked leukopenia with consequent
lung/respiratory dysfunction, which are the characteristics of the most severe
manifestations of the COVID-19 (21,22). Similarly to other respiratory viruses (23-25),
SARS-CoV-2 induces a cytokine storm, characterized by an uncontrolled inflammatory

response mediated by monocytes/macrophages, when they should orchestrate the
antiviral immune response (26,27). In this work, we demonstrate that SARS-CoV-2
infection triggers inflammasome activation, increases IL-1ß secretion by monocytes,
resulting in pyroptotic cell death, which could be a key event for SARS-CoV-2
pathogenesis in critically ill patients and prevented by antiviral drugs (28).

Our results demonstrate that SARS-CoV-2 leads to an intense cell death in human
monocytes, observed by the increase in LDH release in infected cultures as well as by the
higher number of PI$^+$ cells when compared to uninfected controls. Even though the
pretreatment of infected monocytes with the pan-caspase inhibitor ZVAD-FMK
prevented IL-1β secretion, it was not able to prevent the release of LDH. Indeed, others
have demonstrated that the treatment with ZVAD-FMK induces necroptosis in diverse
cell types (29-31). Notably, as pyroptosis is an inflammatory and programmed cell death
mediated by inflammasome and inflammatory caspase-1 activation (13,14), we
investigated the assembly and activation of these structures in human monocytes infected
with SARS-CoV-2. Activation of caspase-1 and increased production of IL-1ß were
observed in infected monocytes. This is correlated to the activation of inflammasomes,
because the pretreatment of infected monocytes with YVAD inhibited the activation of
caspase-1. These results are in accordance with the literature that suggests the formation
of inflammasomes in patients with severe COVID-19 (21). We also showed that the
release of IL-1ß could be promoted by and at the same time amplify the activation of
inflammasomes during the SARS-CoV-2 infection, since the blockage of IL-1ß receptors
reduced caspase-1 activation and cell death. This result corroborates with studies showing
that the increase in IL-1ß production is associated with severe COVID-19 (32-34). Under
our experimental conditions, the increase in IL-1ß precedes the unbalanced IL-6 release.

Monocytes that survived from SARS-CoV-2 infection displayed decreased HLA-
DR expression, which has also been described in monocytes isolated from COVID-19
patients (35,36). Our results suggest that this modulation of HLA expression is not
directly associated with the activation of inflammasomes, and may be involved by other
inflammatory pathways, since we and other have observed increased levels of IL-6 by
myeloid cells impairing HLA-DR membrane expression (37).

To correlate the phenomena of pyroptosis induction and inflammasome activation
observed in our *in vitro* studies with clinical reports in the literature (38,39), we analyzed

peripheral monocytes isolated from patients with severe COVID-19. We found that these cells present higher caspase-1 activation when compared with monocytes isolated from HD. Recent clinical data reports reveal the presence of high levels of LDH and leukopenia in critically ill patients (6,8,40,41). Our data also demonstrate intense monocyte death in COVID-19 patients as detected through flow cytometry analyzes. Altogether, these data suggest that the severity of COVID-19 may be associated with inflammasome activation in monocytes that results in large amounts of IL-1ß and generates an excessive inflammatory response characterized by high levels of IL-6 and TNF-α. Consistently, treatment with IL-1RA has been associated with clinical and inflammatory improvements in critically ill COVID-19 patients (42). These results are in line with clinical case reports that demonstrate that monocytes/macrophages are key cells in the deleterious pro-inflammatory events that characterize the most serious cases of COVID-19 (43-46).

Effective therapies for COVID-19 should combine antiviral with anti-inflammatory properties to reduce viral load and to mitigate the intense inflammatory response. In the present study we used ATV, an antiretroviral approved in 2003 for HIV-1 treatment and previously described by us as having anti-SARS-CoV-2 effects in different cell types (including monocytes) and impairing virus-induced enhancement of IL-6 and TNF-α levels (17). Our data reveal that ATV, besides inhibiting inflammasome and pyroptosis, prevents the decreasing of HLA expression in monocytes infected with SARS-CoV-2. In addition, ATV inhibited the release of LDH and the production of IL-1ß, f IL-6 and TNF-α by SARS-CoV-2-infected monocytes, which are key players in the cytokine storm associated with COVID-19 (47,48).

In this work, we originally describe that infection with SARS-CoV-2 can induce pyroptotic cell death by inflammasome activation, which may be related to the intense leukopenia and exacerbated inflammation seen in severe cases of the COVID-19. Since there is no specific therapy for this disease, our results point out that ATV has a promising therapeutic potential against SARS-CoV-2-induced cell death.

Acknowledgments and funding

We thank the Hemotherapy Service from Hospital Clementino Fraga Filho (Federal University of Rio de Janeiro, Brazil) for providing buffy-coats. This work was supported by grants from Fundação de Amparo a Pesquisa do Estado do Rio de Janeiro

(FAPERJ), Inova Fiocruz, Conselho Nacional de Desenvolvimento Científico e
Tecnológico (CNPq) and Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
(CAPES) and Mercosur Fund for Structural Convergence (FOCEM, Mercosur, grant
number 03/11) granted for Thiago Moreno L. Souza, Patrícia T. Bozza, Fernando A.
Bozza and Dumith Chequer Bou-Habib. Funding was also provided by CNPq, CAPES
and FAPERJ through the National Institutes of Science and Technology Program (INCT)
to Carlos Morel (INCT-IDPN) and to Wilson Savino (INCT-NIM). Thanks are due to
Oswaldo Cruz Foundation/Fiocruz under the auspicious of Inova program. The funding
sponsors had no role in the design of the study; in the collection, analyses, or
interpretation of data; in the writing of the manuscript, and in the decision to publish the
results.

References

1. Conti P, Ronconi G, Caraffa A, Gallenga CE, Ross R, Frydas I, et al. Induction of
pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by COVID-
19: anti-inflammatory strategies. Journal of biological regulators and homeostatic
agents. 2020.

2. Long B, Brady WJ, Koyfman A, Gottlieb M. Cardiovascular complications in
COVID-19. American Journal of Emergency Medicine. 2020.

3. Li J, Fan J-G. Characteristics and Mechanism of Liver Injury in 2019 Coronavirus
Disease. J Clin Transl Hepatol. 2020.

4. Giamarellos-Bourboulis EJ, Netea MG, Rovina N, Akinosoglou K, Antoniadou
A, Antonakos N, et al. Complex Immune Dysregulation in COVID-19 Patients
with Severe Respiratory Failure. Cell Host Microbe. 2020.

5. Du RH, Liang LR, Yang CQ, Wang W, Cao TZ, Li M, et al. Predictors of mortality
for patients with COVID-19 pneumonia caused by SARSCoV- 2: A prospective
cohort study. Eur Respir J. 2020.

6. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors
for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective
cohort study. Lancet. 2020.

7.   Wölfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Müller MA, et al.
Virological assessment of hospitalized patients with COVID-2019. Nature. 2020.

8.   Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. Pathological findings of
COVID-19 associated with acute respiratory distress syndrome. Lancet Respir
Med. 2020.

9.   Han Y, Zhang H, Mu S, Wei W, Jin C, Xue Y, et al. Lactate dehydrogenase, a
Risk Factor of Severe COVID-19 Patients. medRxiv. 2020.

10.   Terpos E, Ntanasis-Stathopoulos I, Elalamy I, Kastritis E, Sergentanis TN, Politou
M, et al. Hematological findings and complications of COVID-19. American
Journal of Hematology. 2020.

11.   Li YX, Wu W, Yang T, Zhou W, Fu YM, Feng QM, et al. [Characteristics of
peripheral blood leukocyte differential counts in patients with COVID-19].
Zhonghua nei ke za zhi. 2020.

12.   Ding X, Yu Y, Lu B, Huo J, Chen M, Kang Y, et al. Dynamic profile and clinical
implications of hematological parameters in hospitalized patients with
coronavirus disease 2019. Clin Chem Lab Med. 2020.

13.   Singh A, Sood N, Narang V, Goyal A. Morphology of COVID-19-affected cells
in peripheral blood film. BMJ Case Reports. 2020.

14.   Zalinger ZB, Elliott R, Weiss SR. Role of the inflammasome-related cytokines Il-
1 and Il-18 during infection with murine coronavirus. J Neurovirol. 2017.

15.   Franchi L, Eigenbrod T, Muñoz-Planillo R, Nuñez G. The inflammasome: A
caspase-1-activation platform that regulates immune responses and disease
pathogenesis. Nature Immunology. 2009.

16.   Miao EA, Rajan J V., Aderem A. Caspase-1-induced pyroptotic cell death.
Immunological Reviews. 2011.

17.   Fintelman-Rodrigues N, Sacramento CQ, Lima CR, Silva FS da, Ferreira A,
Mattos M, et al. Atazanavir inhibits SARS-CoV-2 replication and pro-
inflammatory cytokine production. bioRxiv. 2020.

18.   OPAS. COVID-19 (doença causada pelo novo coronavírus). Folha Inf. 2020.

19.   Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-
19 in real time. The Lancet Infectious Diseases. 2020.

20.   Wissel BD, Van Camp PJ, Kouril M, Weis C, Glauser TA, White PS, et al. An
Interactive Online Dashboard for Tracking COVID-19 in U.S. Counties, Cities,
and States in Real Time. J Am Med Inform Assoc. 2020.

21.   Lucas C, Wong P, Klein J, Castro TBR, Silva J, Sundaram M, et al. Longitudinal
analyses reveal immunological misfiring in severe COVID-19. Nature. 2020.

22.   Tay MZ, Poh CM, Rénia L, MacAry PA, Ng LFP. The trinity of COVID-19:
immunity, inflammation and intervention. Nature Reviews Immunology. 2020.

23.   Teijaro JR. The role of cytokine responses during influenza virus pathogenesis
and potential therapeutic options. Curr Top Microbiol Immunol. 2014.

24.   Szretter KJ, Gangappa S, Lu X, Smith C, Shieh W-J, Zaki SR, et al. Role of Host
Cytokine Responses in the Pathogenesis of Avian H5N1 Influenza Viruses in
Mice. J Virol. 2007.

25.   Peschke T, Bender A, Nain M, Gemsa D. Role of Macrophage Cytokines in
Influenza A Virus lnfections. Immunobiology. 1993.

26.   Woo PCY, Tung ETK, Chan KH, Lau CCY, Lau SKP, Yuen KY. Cytokine
profiles induced by the novel swine-origin influenza A/H1N1 virus: Implications
for treatment strategies. J Infect Dis. 2010.

27.   Jamilloux Y, Henry T, Belot A, Viel S, Fauter M, El Jammal T, et al. Should we
stimulate or suppress immune responses in COVID-19? Cytokine and anti-
cytokine interventions. Autoimmunity Reviews. 2020.

28. Zheng Z, Peng F, Xu B, Zhao J, Liu H, Peng J, et al. Risk factors of critical &
mortal COVID-19 cases: A systematic literature review and meta-analysis.
Journal of Infection. 2020.

29. Siegmund D, Kums J, Ehrenschwender M, Wajant H. Activation of TNFR2
sensitizes macrophages for TNFR1-mediated necroptosis. Cell Death Dis. 2016.

30. Kim SJ, Li J. Caspase blockade induces RIP3-mediated programmed necrosis in
Toll-like receptor-activated microglia. Cell Death Dis. 2013.

31. Wu YT, Tan HL, Huang Q, Sun XJ, Zhu X, Shen HM. ZVAD-induced necroptosis
in L929 cells depends on autocrine production of TNFα mediated by the PKC-
MAPKs-AP-1 pathway. Cell Death Differ. 2011.

32. Abbasifard M, Khorramdelazad H. The bio-mission of interleukin-6 in the
pathogenesis of COVID-19: A brief look at potential therapeutic tactics. Life
Sciences. 2020.

33. Yao Z, Zheng Z, Wu K, Zheng J. Immune environment modulation in pneumonia
patients caused by coronavirus: SARS-CoV, MERS-CoV and SARS-CoV-2.
Aging (Albany NY). 2020.

34. Zhang Y, Li J, Zhan Y, Wu L, Yu X, Zhang W, et al. Analysis of serum cytokines
in patients with severe acute respiratory syndrome. Infect Immun. 2004.

35. Ong EZ, Chan YFZ, Leong WY, Lee NMY, Kalimuddin S, Haja Mohideen SM,
et al. A Dynamic Immune Response Shapes COVID-19 Progression. Cell Host
Microbe. 2020.

36. Laing AG, Lorenc A, del Molino del Barrio I, Das A, Fish M, Monin L, et al. A
dynamic COVID-19 immune signature includes associations with poor prognosis.
Nat Med [Internet]. 2020; Available from: https://doi.org/10.1038/s41591-020-
1038-6.

37. Ohno Y, Kitamura H, Takahashi N, Ohtake J, Kaneumi S, Sumida K, et al. IL-6
down-regulates HLA class II expression and IL-12 production of human dendritic
cells to impair activation of antigen-specific CD4+ T cells. Cancer Immunol

Immunother. 2016.

38.   Yap JKY, Moriyama M, Iwasaki A. Inflammasomes and Pyroptosis as Therapeutic
Targets for COVID-19. J Immunol. 2020.

39.   Rodrigues S, de Sá KS, Ishimoto AY, Becerra A, Oliveira S, Almeida L, et al.
Inflammasome activation in COVID-19 patients 1 2 Tamara. medRxiv. 2020.
511

40.   Yuan J, Zou R, Zeng L, Kou S, Lan J, Li X, et al. The correlation between viral
clearance and biochemical outcomes of 94 COVID-19 infected discharged
patients. Inflamm Res. 2020.

41.   Yan L, Zhang HT, Goncalves J, Xiao Y, Wang M, Guo Y, et al. An interpretable
mortality prediction model for COVID-19 patients. Nat Mach Intell. 2020.

42.   Cauchois R, Koubi M, Delarbre D, Manet C, Carvelli J, Blasco VB, et al. Early
IL-1 receptor blockade in severe inflammatory respiratory failure complicating
COVID-19. Proc Natl Acad Sci. 2020.

43.   Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, et al. Dysregulation of immune
response in patients with COVID-19 in Wuhan, China. Clin Infect Dis. 2020.

44.   McGonagle D, Sharif K, O'Regan A, Bridgewood C. The Role of Cytokines
including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage
Activation Syndrome-Like Disease. Autoimmunity Reviews. 2020.

45.   Merad M, Martin JC. Pathological inflammation in patients with COVID-19: a key
role for monocytes and macrophages. Nature Reviews Immunology. 2020.

46.   Park MD. Macrophages: a Trojan horse in COVID-19? Nat Rev Immunol. 2020.
528

529   47.   Hantoushzadeh S, Norooznezhad AH. Possible Cause of Inflammatory Storm and
530   Septic Shock in Patients Diagnosed with (COVID-19). Arch Med Res. 2020.

531   48.   Hantoushzadeh S, Norooznezhad AH. Inappropriate Antibiotic Consumption as a
532   Possible Cause of Inflammatory Storm and Septic Shock in Patients Diagnosed
533   with Coronavirus Disease 2019 (COVID-19). Arch Med Res. 2020.

 FIGURE LEGENDS

Figure 1. SARS-Cov-2 induces monocyte cell death through pyroptosis. Human

monocytes were pretreated with caspase-1 inhibitor (AC-YVAD-CMK – 1 μM), pan-

caspase inhibitor (ZVAD-FMK - 10 μM) or necroptosis inhibitor (Nec-1 - 25 μM) for 1

h and infected with SARS-Cov-2 (MOI 0.1) for 24 h. As a positive control, monocytes

were stimulated with LPS (500ng/mL) for 23 h and after this time, incubated with ATP

(2 mM) for 1 h. **(A)** Cell viability was assessed through the measurement of LDH release

in the supernatant of monocytes. **(B, C)** Monocytes` monolayers were stained with

propidium iodide (PI) plus Annexin V and pyroptotic cell death were determine by flow

cytometer analysis and **(D)** labeled with DAPI to visualize the nuclei fluorescence

microscopy. Images and Graph data are representative of six independent experiments.

Data are presented as the mean ± SEM * $P < 0.05$ *versus* control group (MOCK); $^\#$ $P <$

0.05 *versus* infected and untreated group (Nil).

Figure 2. SARS-CoV-2 induce inflammasome activation in human monocytes.

Human monocytes were pretreated with caspase-1 inhibitor (AC-YVAD-CMK – 1 μM),

pan-caspase inhibitor (ZVAD-FMK - 10 μM), necroptosis inhibitor (Nec-1 - 25 μM) or

inhibitor of IL-1ß receptor (IL-1RA – 1 μM) for 1 h and infected with SARS-Cov-2 (MOI

0.1) for 24 h. Monocytes were stimulated with LPS (500ng/mL) for 23 h and after this

time were stimulated with ATP (2 mM) for 1 h as a positive control group for the

formation of inflammasomes and pyroptosis induction. **(A)** Monocytes` monolayers were

used for determination of the levels of pro-caspase-1 and cleaved caspase-1 by western

blot analysis. **(B, C)** Monocytes were stained with FAM-YVAD-FLICA and FAM-

FLICA to determine the caspase-1 and caspase-3/7 activity, respectively, by flow

cytometry. **(D)** Cell culture supernatants were collected for the measurement of the levels

of LDH **(F)**. Western blot, histogram and graph data are representative of six independent

experiments. Data are presented as the mean ± SEM $^\#$ $P < 0.05$ *versus* infected and

untreated group (Nil); * $P < 0.05$ *versus* positive control group (LPS+ATP).

Figure 3. Inflammasome activation amplify pro-inflammatory cytokines secretion

in infected monocytes. Human monocytes were pretreated with caspase-1 inhibitor (AC-

YVAD-CMK – 1 μM), pan-caspase inhibitor (ZVAD-FMK - 10 μM), necroptosis

inhibitor (Nec-1 - 25 μM). Monocytes were stimulated with LPS (500ng/mL) for 23 h

and after this time were stimulated with ATP (2 mM) for 1 h as a positive control group

for the formation of inflammasomes and pyroptosis induction. Cell culture supernatants
were collected for the measurement of the levels of **(A)** IL-1β, **(B)** IL-8, **(C)** IL-6 and **(D)**
TNF-α. Graphs data are representative of six independent experiments. Data are presented
as the mean ± SEM [#] $P < 0.05$ *versus* infected and untreated group (Nil); [*] $P < 0.05$ *versus*
positive control group (LPS+ATP).

Figure 4. Infection with SARS-CoV-2 decreases the expression of HLA in human
monocytes independently of the activation of inflammasomes. Human monocytes
were pretreated with caspase-1 inhibitor (AC-YVAD-CMK – 1 µM) or inhibitor of IL-
1ß receptor (IL-1RA – 1 µM) for 1 h and infected with SARS-Cov-2 for 24 h. **(A, B)**
Monocytes were stained with HLA-DR APC.H7 or IgG APC.H7 to determine the HLA-
DR expression by flow cytometry. **(C, D)** mean fluorescence intensity (MFI) value for
each sample was represented in graphics. Histogram and graphs datas are representative
of two independent experiments. Data are presented as the mean ± SEM [#] $P < 0.05$ *versus*
uninfected group (MOCK).

Figure 5. Atazanavir prevented inflammasome-dependent pyroptosis. Human
monocytes were infected with SARS-Cov-2 and treated with atazanavir – ATV (10 µM),
ribavirina (10 µM) or Lopinavir (10 µM) for 24 h. **(A, B)** Monocytes were stained with
FAM-YVAD-FLICA or FAM-FLICA and HLA-DR APC.H7 or IgG APC.H7 to
determine the caspase-1 and caspase-3/7 activity and HLA-DR expression, respectively
and analyzed by flow cytometry. **(C – F)** Culture supernatants were collected and the
levels of IL-1β, IL-8, IL-6 and TNF-α were determined by ELISA. **(G)** Assessment of
cell viability through the measurement of LDH release in the supernatant of monocytes.
Histogram and graphs datas are representative of six independent experiments. Data are
presented as the mean ± SEM [*] $P < 0.05$ *versus* control group (MOCK); [#] $P < 0.05$ *versus*
only infected group (Nil).

Figure 6. Inflammasome activation and pyroptosis are risk factors in critically ill
COVID-19 patients. Monocytes isolated from blood samples of critically ill patients
with COVID-19 and healthy donors. **(A)** Monocytes` extracts were used for to determine
the levels of pro-caspase-1 and cleaved caspase-1 and IL-1β by western blot analysis. In
addition, **(B and C, respectively)** monocytes were stained with FAM-YVAD-FLICA or
propidium iodide (PI) and analyzed by flow cytometry. **(D)** plasma was separated and the
levels of IL-1β were determined by ELISA. Western blot, histogram and graphs datas are

representative of 9 critically ill patients and 8 healthy donors. Data are presented as the

mean $\pm$ SEM [*] $P < 0.05$ *versus* healthy donors (HD).

Figure 7. Representative scheme of the SARS-CoV-2 infection in activation of

inflammasome and pyroptosis in monocyte with downregulation of HLA-DR expression

and effects of ATV treatment in this phenomenon.

620 **Table 1:** Characteristics of COVID-19 patients and control subjects.

Characteristics[1]	Control (N=8)	Covid-19 (N=9)
Age, years	52.6 (47 – 60)	61 (33 – 79)
Sex, male	8 (100 %)	6 (66.7 %)
Respiratory support		
Oxygen supplementation	0 (0 %)	3 (33.3 %)
Mechanical ventilation	0 (0 %)	6 (66.7 %)
SAPS 3		59.25 (31 – 75)
PaO2/FiO2 ratio	-	210.75 (87 – 509.5)
Vasopressor	-	3 (33.3 %)
Time from symptom onset to blood sample, days	-	10 (6 – 18)
Status on Jun 30th		
Dead	-	5 (55.55 %)
Discharged	-	1 (11.1 %)
Hospitalized	-	3 (33.3 %)
Comorbidities		
Obesity	1 (11.1 %)	1 (11.1 %)
Hypertension	3 (33.3%)	3 (33.3 %)
Diabetes	0 (0%)	0 (0 %)
Cancer	0 (0%)	0 (0 %)
Chronic heart disease[2]	0 (0%)	0 (0 %)
Presenting symptoms		
Cough	0 (0 %)	3 (33,3 %)
Fever	0 (0 %)	3 (33,3 %)
Dyspnea	0 (0 %)	4 (44,4 %)
Headache	0 (0 %)	0 (0 %)
Anosmia	0 (0 %)	0 (0 %)
Laboratory findings on admission		
Lymphocyte count, cells/mm^3	-	1,355.8 (552 –2,564)
Platelet count, x 1000/mm^3	-	169.6 (92 – 278)
Leukocytes	-	8,036 (8.03-18,670)
C Reactive Protein, mg/L	-	14.78 (0.1 – 30.8)

FIGURE 1

684   **FIGURE 2**

716   '

718 **FIGURE 3**

FIGURE 4

FIGURE 5

FIGURE 6

     FIGURE 7

868 **FIGURE S1**
869
870

885 **S1 Fig. Evaluation of anti-inflammatory activity of ATV, LPV and ribavirin in LPS-induced monocytes.** Human monocytes were stimulated
886 with LPS (500ng/mL) for 23 h and after this time were stimulated with ATP (2 mM) for 1 h as a positive control group for the formation of
887 inflammasomes and pyroptosis induction. Simultaneously, cells were treated with atazanavir – ATV (10 µM), LPV (10 µM) or ribavirin (10 µM)
888 for 24 h. Monocytes were stained with FAM-YVAD-FLICA (blue) or FAM-FLICA (green) to determine the caspase-1 and caspase-3/7 activity
889 and HLA-DR expression, respectively, and analyzed by flow cytometry. Histograms are representative of six independent experiments.

890
891
892
893
894 **FIGURE S2**

924 **S2 Fig. Effects of LPV and ribavirin in preventing the SARS-CoV-2-related reduced**

925 **expression of HLA-DR in monocytes.** Human monocytes were infected with SARS-

926 Cov-2 and treated with LPV (10 µM) or ribavirina (10 µM) for 24 h. Monocytes were

927 stained with HLA-DR APC.H7 or IgG APC.H7 to determine the HLA-DR expression by

928 flow cytometry. Histogram data are representative of two independent experiments.

929
930
931
932
933